“…With the far-reaching impacts of injuries in LMICs [ 1-5 , 29 ] and the limited available research from these settings, additional study of blood product therapies, which are key to combating injury-related mortality, is crucial for informing clinical practice and policy. [42] 3, 5 Low Javali (2017) [43] 3 Moderate Kilyewala (2017) [57] 3, 4, 5 Very Low London (2001) [41] 2, 4 Low Mofidi (2010) [47] 2, 4, 5 Very Low Musau (2006) [50] 3, 4 Low Newton (2015) [51] 1, 3, 4, 5 Very Low Otieno (2004) [52] 3, 4 Low Sadeghi (2017) [48] 2, 3 Low Saidi (2014) [53] 3, 5 Low Sokhal (2017) [44] 3, 5 Low Srikant (2003) [45] 1, 3, 4 Very Low Tavousi (2018) [49] 3, 5 Low Yanar (2008) [56] 3 There is substantial research, including well-performed RCTs from HICs, that has led to development of consensus guidelines on the use of blood products in the treatment of acute injuries [ 14-16 , 18 , 59 , 60 ] [ 8 , 18 , 61 , 62 ]. Even though the global burden of injuries lies predominantly in LMICs [ 1-5 , 29 ], this systematic review demonstrates that there is a paucity of high-quality research from these settings.…”